Emcure Pharmaceuticals has announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its active pharmaceutical ingredient (API) manufacturing facility located in Kurkumbh, Taluka – Daund, Pune, Maharashtra.
The inspection, which was previously communicated by the company on February 26, 2025, has been classified by the USFDA as “Voluntary Action Indicated” (VAI). This classification indicates that the facility may have some objectionable conditions or practices, but regulatory action is not currently being recommended. The company is expected to take voluntary corrective actions to address the issues identified.
The Kurkumbh facility is a key part of Emcure’s API manufacturing operations. Receipt of the EIR and the VAI status suggests that while the facility remains operational, it will need to implement improvements in line with regulatory expectations.
